Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03512015 | A Mobile Supportive Care App for Patients With Metastatic Lung Cancer(LuCApp) | unknown | N/A | 120 | Bocconi UniversityOTHER | 0 | Apr 30, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development Limited |
| 1 |
| Apr 25, 2018 |
| clinicaltrials |
| NCT02134990 | Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer | unknown | Phase 2 | 20 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT03489616 | Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients(CRAGMOLC) | unknown | N/A | 45 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation(Geber) | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 3, 2018 | clinicaltrials |
| NCT03471884 | Effects of Nonintubated Thoracoscopic Lobectomy on Lung Protection | unknown | N/A | 82 | National Taiwan University HospitalOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03460275 | Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT03461185 | Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 100 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02778854 | Liquid Biopsy for Detection of Driver Mutation in NSCLC | unknown | — | 200 | Chinese PLA General HospitalOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT03453307 | Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients | unknown | — | 100 | K2 Oncology, Inc.INDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01102517 | A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung Cancer | unknown | N/A | 500 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03446911 | Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery | unknown | Phase 1 / Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT03432637 | Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia | unknown | Phase 3 | 450 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT03427541 | A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases | unknown | — | 1,000 | Tang-Du HospitalOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT03424759 | Uncommon EGFR AZD9291 | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02151721 | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer(VICTORY-J) | unknown | Phase 1 | 12 | Kanazawa UniversityOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03416231 | Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 2 | 20 | Affiliated Hospital of North Sichuan Medical CollegeOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT03416972 | Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy(RICT-LUNG) | unknown | — | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT03413358 | Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid | unknown | N/A | 240 | BeiJing Yijiayi Medicine Techonoloy Co., Ltd.INDUSTRY | 1 | Jan 29, 2018 | clinicaltrials |
| NCT02734524 | A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 2 | 104 | Southwest Hospital, ChinaOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02852083 | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC(ModuLung) | unknown | Phase 2 | 86 | University Hospital RegensburgOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02934360 | TR(ACE) Assay Clinical Specimen Study | unknown | — | 450 | Biological DynamicsINDUSTRY | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03127319 | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | unknown | Phase 2 | 40 | Affiliated Hospital of Hebei UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03399669 | The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation | unknown | Phase 2 | 100 | Samsung Medical CenterOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02410369 | Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer | unknown | Phase 2 | 60 | Tokyo UniversityOTHER | 1 | Dec 21, 2017 | clinicaltrials |
| NCT03376191 | Apatinib in Advanced Non-squamous，NSCLC | unknown | — | 100 | Jian FangOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03341494 | EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide | unknown | Phase 2 | 128 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03262948 | Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer | unknown | Phase 3 | 388 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02397239 | Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer | unknown | — | 72 | National Cheng-Kung University HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03331575 | Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC(HCFCCUSN) | unknown | Phase 3 | 480 | Shanghai Chest HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02714010 | EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC | unknown | Phase 3 | 601 | Sun Yat-sen UniversityOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02499614 | Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)(METROS) | unknown | Phase 2 | 80 | Fondazione Ricerca TraslazionaleOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT03198923 | Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer | unknown | Phase 1 | 30 | Wenxiang WangOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT02455843 | Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC | unknown | Phase 3 | 275 | Shandong Provincial HospitalOTHER_GOV | 1 | Sep 19, 2017 | clinicaltrials |
| NCT02894853 | Lung Cancer Early Molecular Assessment Trial(LEMA) | unknown | — | 1,297 | The Netherlands Cancer InstituteOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT03269162 | Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection | unknown | Phase 3 | 144 | lihegenOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT03282435 | Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody | unknown | Phase 1 | 30 | Dalian UniversityOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT03264794 | the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) | unknown | Phase 4 | 100 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Aug 29, 2017 | clinicaltrials |
| NCT03258671 | IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer | unknown | N/A | 160 | LuBingOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | unknown | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02515435 | The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 40 | Tongji UniversityOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT03065764 | 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer | unknown | Phase 2 | 10 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02404675 | High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation(INCREASE) | unknown | Phase 4 | 240 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03228368 | The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients | unknown | — | 10 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jul 24, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Apr 30, 2018source: clinicaltrials